• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global API Market Forecast to 2017 - Product Image

Global API Market Forecast to 2017

  • Published: July 2013
  • Region: Global
  • 105 Pages
  • RNCOS E-Services Private Limited

FEATURED COMPANIES

  • Aurobindo Pharma Limited
  • BASF SE
  • Boehringer Ingelheim GmbH
  • Cambrex Corporation
  • Cipla
  • Daiichi Fine Chemicals
  • MORE

The market for Active Pharmaceutical Ingredients is brimming with activities. While it is consolidating in US and EU resulting in the emergence of few big players producing specialty APIs that target high value markets, new players are entering in the mass markets of India and China. With global healthcare spending to have reached around US$ 6.4 Trillion in 2010 and a rapidly ageing population boosting the demand for pharmaceuticals, APIs represent one of the most exciting markets for growth.

In this latest research study, ""Global API Market Forecast to 2017"", the authors identified market dynamics in various important regions to highlight the areas offering promising possibilities for companies to boost their growth. The market, which stood at US$ 113 Billion in 2012, is expected to grow at a CAGR of around 8% during 2012-2017.

For this study, the authors have analyzed the global API market from different perspectives. It has been studied at the “Captive vs. Merchant” level; “Branded vs. Generic” level and “Synthetic vs. Biotech level”. This has been done to provide a thorough and apt assessment to players who can use the research READ MORE >

1. Analyst View

2. Research Methodology

3. APIs - An Introduction

4. Industry Performance
4.1 Current and Future Market Analysis to 2017
4.2 Market Segments
4.2.1 Branded and Generic APIs
4.2.2 Synthetic and Biotech APIs
4.3 Future Opportunity Assessment

5. Countries’ Comparative Analysis: API Manufacturing
5.1 Labor Cost and Productivity
5.2 Price Structure
5.3 Investment Cost in Plant Set-up

6. Analysis by Therapeutic Segments
6.1 Central Nervous System Disorders
6.2 Cardiovascular Diseases
6.3 Diabetes
6.4 Respiratory Disorders
6.5 Oncology

7. Key Geographical Markets
7.1 China
7.1.1 Current and Future Market Analysis to 2017
7.1.2 Regional Segmentation
7.1.3 Regulatory Environment
7.1.4 Future Opportunity Assessment
7.2 India
7.2.1 Current and Future Market Analysis to 2017
7.2.2 Regional Segmentation
7.2.3 Regulatory Environment
7.2.4 Future Opportunity Assessment
7.3 Italy
7.3.1 Current and Future Market Analysis to 2017
7.3.2 Regulatory Environment
7.3.3 Future Opportunity Assessment
7.4 Taiwan

8. High-Potency APIs: An Emerging Opportunity

9. Regulatory Environment

10. Competitive Landscape
10.1 Dr Reddy’s Laboratories
10.2 Cipla
10.3 Ranbaxy Laboratories
10.4 Zhejiang Hisun Pharmaceutical Co. Ltd.
10.5 Fabbrica Italiana Sintetici
10.6 Cambrex Corporation
10.7 Pfizer CentreSource
10.8 Teva Active Pharmaceutical Ingredients
10.9 Lonza
10.10 Daiichi Fine Chemicals
10.11 Boehringer Ingelheim GmbH
10.12 BASF SE
10.13 Royal DSM
10.14 Divis Laboratories Limited
10.15 Aurobindo Pharma Limited

List of Tables

Table 3-1: Classification of Bulk Drugs
Table 5-1: Global - Fine Chemical Industry Labor Cost and Productivity in Key Regions (2010)
Table 5-2: Global - Investment Cost Comparison for Multi-Purpose Pharmaceutical Fine Chemical Plants in Key Countries
Table 7-1: China - Number of API Companies by Province
Table 7-2: India - Number of Bulk Drugs Manufacturing Units
Table 7-3: Taiwan - Number of Pharmaceutical Licenses by Type (2010)
Table 9-1: Scope of Authority for Regulatory Agencies
Table 10-1: Dr. Reddy's Laboratories - Strengths and Weaknesses
Table 10-2: Cipla - Strengths and Weaknesses
Table 10-3: Ranbaxy Laboratories - Strengths and Weaknesses
Table 10-4: Zhejiang Hisun Pharmaceutical - Strengths and Weaknesses
Table 10-5: Fabbrica Italiana Sintetici - Strengths and Weaknesses
Table 10-6: Cambrex Corporation - Strengths and Weaknesses
Table 10-7: Pfizer CentreSource - Strengths and Weaknesses
Table 10-8: Teva Active Pharmaceutical Ingredients - Strengths and Weaknesses
Table 10-9: Lonza - Strengths and Weaknesses
Table 10-10: Daiichi Fine Chemical - Strengths and Weaknesses
Table 10-11: Boehringer Ingelheim - Strengths and Weaknesses
Table 10-12: BASF - Strengths and Weaknesses
Table 10-13: Royal DSM - Strengths and Weaknesses
Table 10-14: Divis Laboratories Limited - Strengths and Weaknesses
Table 10-15: Aurobindo Pharma Limited - Strengths and Weaknesses

List of Charts

Figure 4-1: Global - API Market (Billion US$), 2012-2017
Figure 4-2: Global - Share of Captive and Merchant Market in API Market (2012)
Figure 4-3: Global - API Captive Market (Billion US$), 2012-2017
Figure 4-4: Global - API Merchant Market (Billion US$), 2012-2017
Figure 4-5: Global - Share of Branded and Generic APIs in API Merchant Market (2012)
Figure 4-6: Global - Generic API Merchant Market (Billion US$), 2012-2017
Figure 4-7: Global - Branded API Merchant Market (Billion US$), 2012-2017
Figure 4-8: Global - Share of Synthetic and Biotech APIs in API Market (2012)
Figure 5-1: Global - Price Structure for Pharmaceutical Fine Chemicals in US, India and China (%)
Figure 7-1: China - Pharmaceutical Industry by Segment (2010)
Figure 7-2: China - API Merchant Market (Billion US$), 2012-2017
Figure 7-3: China - Share in Global API Merchant Market (2012)
Figure 7-4: China - Generic API Merchant Market (Billion US$), 2012-2017
Figure 7-5: China - Share in Global Generic API Merchant Market (2012)
Figure 7-6: India - API Merchant Market (Billion US$), 2012-2017
Figure 7-7: India - Share in Global API Merchant Market (2012)
Figure 7-8: India - Generic API Merchant Market (Billion US$), 2012-2017
Figure 7-9: India - Share in Global Generic API Merchant Market (2012)
Figure 7-10: Italy - API Merchant Market (Billion US$), 2012-2017
Figure 7-11: Italy - Share in Global API Merchant Market (2012)
Figure 7-12: Italy - Number of API Producers and Manufacturing Plants (1991, 2000 & 2009)
Figure 7-13: Italy - Generic API Merchant Market (Billion US$), 2012-2017
Figure 7-14: Italy - Share in Global Generic API Merchant Market (2012)
Figure 7-15: Taiwan - API Market (Billion NT$), 2010 & 2011
Figure 8-1: Global - HPAPI Market (Billion US$), 2012-2017
Figure 8-2: Global - Share of Synthetic and Biotech HPAPIs in HPAPI Market (2012)
Figure 8-3: Global - Share of Generics and Branded in HPAPI Market (2012)

- Aurobindo Pharma Limited
- BASF SE
- Boehringer Ingelheim GmbH
- Cambrex Corporation
- Cipla
- Daiichi Fine Chemicals
- Divis Laboratories Limited
- Dr Reddy’s Laboratories
- Fabbrica Italiana Sintetici
- Lonza
- Pfizer CentreSource
- Ranbaxy Laboratories
- Royal DSM
- Teva Active Pharmaceutical Ingredients
- Zhejiang Hisun Pharmaceutical Co. Ltd.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos